BioCentury | Sep 22, 2014

Weighing in on obesity

Contrave naltrexone/bupropion will be the first new obesity drug launched in the past two years to have the full weight of a large pharma partner with an established commercial footprint in the cardiometabolic space behind...
BC Week In Review | Jun 18, 2012
Company News

Proximagen, Upsher-Smith deal

Specialty pharma Upsher-Smith will acquire the 84% of Proximagen it does not already own for 320p per share in cash. The price, which values Proximagen at about £223 million ($345.7 million), is a 16% premium...
BC Extra | Jun 14, 2012
Company News

Upsher-Smith to acquire Proximagen

Specialty pharma Upsher-Smith Laboratories Inc. (Maple Grove, Minn.) will acquire the 84% of Proximagen Group plc (LSE:PRX) it does not already own for 320p per share in cash. The price, which values Proximagen at about...
BC Week In Review | Dec 5, 2011
Company News

Altacor, Proximagen deal

The companies partnered to develop Proximagen's programs targeting the serotonin (5-HT2C) receptor for ophthalmic indications. Altacor will fund preclinical work of PRX00933 , the lead compound under the program, to treat glaucoma. Altacor will receive an...
BioCentury | Feb 7, 2011
Product Development

Obesity Reset

Even after FDA rejected the advice of its advisory committee and requested a cardiovascular outcomes trial of Orexigen Inc. 's Contrave bupropion/naltrexone to treat obesity, companies with earlier stage programs remain hopeful they will be...
BC Innovations | Nov 18, 2010
Distillery Therapeutics

Indication: Endocrine disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine disease Diabetes Serotonin (5-HT2C) receptor Mouse studies suggest that increasing 5-HT2C receptor activation on proopiomelanocortin (POMC) neurons could help treat diabetes. In mice, global 5-HT2C...
Items per page:
1 - 6 of 6